登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study
ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由重庆医科大学附属第一医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07324473,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Patients with a diagnosis of hepatocellular carcinoma, confirmed either by clinical diagnosis (per the Chinese Guidelines for the Diagnosis and Treatment of Primary Liver Cancer [2022 Edition]) or by pathological diagnosis.
入选标准第 1 条
Patients with unresectable hepatocellular carcinoma who have developed secondary (acquired) drug resistance. This is defined as having received at least 4 cycles of a first-line targeted therapy combined with immunotherapy regimen recommended by guidelines . Eligible prior regimens include specified combinations (e.g., Camrelizumab + Apatinib; Atezolizumab + Bevacizumab; Sintilimab + Bevacizumab) or other guideline-recommended first-line targeted agents (Donafenib, Lenvatinib, Sorafenib, Cabozantinib, Regorafenib) combined with first-line immunotherapy (Tislelizumab, Durvalumab, Pembrolizumab). Furthermore, patients must have achieved a partial response in the primary lesion but subsequently experienced disease progression after the 4th immunotherapy cycle, as confirmed per RECIST 1.1 criteria (including increase in size of primary lesion, or emergence of new lesions/metastases).
入选标准第 3 条
For female study participants of childbearing potential, a negative urine or serum pregnancy test must be obtained within 3 days prior to the first dose of study drug (Cycle 1, Day 1). If the urine pregnancy test result is not confirmatory, a serum pregnancy test is required. A female not of childbearing potential is defined as being postmenopausal for at least 1 year, or surgically sterilized, or having undergone a hysterectomy.
入选标准第 8 条
Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.
入选标准第 6 条
At least one measurable lesion according to RECIST 1.1 criteria (target lesion with longest diameter ≥ 10 mm, or lymph node with short axis ≥ 15 mm).
入选标准第 4 条
1. Diagnosis of malignancies other than liver cancer within 5 years prior to the first dose.
排除标准第 1 条
History of immunodeficiency; positive HIV antibody test; current long-term use of systemic corticosteroids or other immunosuppressants; active autoimmune disease requiring systemic treatment within the past two years.
排除标准第 8 条
Pregnant or lactating women.
排除标准第 13 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07324473,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Patients with a diagnosis of hepatocellular carcinoma, confirmed either by clinical diagnosis (per the Chinese Guidelines for the Diagnosis and Treatment of Primary Liver Cancer [2022 Edition]) or by pathological diagnosis. Patients classified as Barcelona Clinic Liver Cancer (BCLC) stage B and assessed by the responsible hepatobiliary surgeon as unsuitable for radical resection, or patients with BCLC stage C disease. Patients with unresectable hepatocellular carcinoma who have developed secondary (acquired) drug resistance. This is defined as having received at least 4 cycles of a first-line targeted therapy combined with immunotherapy regimen recommended by guidelines . Eligible prior regimens include specified combinations (e.g., Camrelizumab + Apatinib; Atezolizumab + Bevacizumab; Sintilimab + Bevacizumab) or other guideline-recommended first-line targeted agents (Donafenib, Lenvatinib, Sorafenib, Cabozantinib, Regorafenib) combined with first-line immunotherapy (Tislelizumab, Durvalumab, Pembrolizumab). Furthermore, patients must have achieved a partial response in the primary lesion but subsequently experienced disease progression after the 4th immunotherapy cycle, as confirmed per RECIST 1.1 criteria (including increase in size of primary lesion, or emergence of new lesions/metastases). At least one measurable lesion according to RECIST 1.1 criteria (target lesion with longest diameter ≥ 10 mm, or lymph node with short axis ≥ 15 mm). Anticipated life expectancy > 3 months. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1. Adequate organ and bone marrow function, as evidenced by the following laboratory values within 7 days prior : (1)Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L in the absence of granulocyte colony-stimulating factor support within the last 14 days; (2)Platelets ≥ 60 × 10⁹/L without transfusion within the last 14 days; (3)Hemoglobin > 9 g/dL without transfusion or erythropoietin use within the last 14 days; (4)Total bilirubin ≤ 2 × upper limit of normal (ULN); (5)Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN; (6)Serum creatinine ≤ 1.5 × ULN and creatinine clearance (calculated using the Cockcroft-Gault formula) ≥ 60 mL/min; (7)Adequate coagulation function, defined as an International Normalized Ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN; (8)Normal thyroid function, defined as thyroid-stimulating hormone (TSH) within the normal range. If baseline TSH is outside the normal range, study participants may still be enrolled if total T3 (or free T3) and free T4 are within the normal range; (9)Myocardial enzyme profile within normal limits (isolated laboratory abnormalities judged by the investigator as clinically insignificant are also permitted); For female study participants of childbearing potential, a negative urine or serum pregnancy test must be obtained within 3 days prior to the first dose of study drug (Cycle 1, Day 1). If the urine pregnancy test result is not confirmatory, a serum pregnancy test is required. A female not of childbearing potential is defined as being postmenopausal for at least 1 year, or surgically sterilized, or having undergone a hysterectomy.排除标准:Exclusion Criteria:
1. Diagnosis of malignancies other than liver cancer within 5 years prior to the first dose. Intrahepatic or extrahepatic cholangiocarcinoma, combined hepatocellular-cholangiocarcinoma, sarcomatoid hepatocellular carcinoma, fibrolamellar HCC, ampullary tumors, or other biliary tract malignancies. Prior treatment with any JAK inhibitor. Patients with pleural effusion, ascites, or pericardial effusion requiring drainage, who are clinically assessed as unable to tolerate the study treatment. History of esophageal or gastric variceal bleeding due to portal hypertension within 6 months prior to the first dose; or current imaging (contrast-enhanced CT or MRI) confirming significant esophageal or gastric varices. History of severe bleeding tendency or coagulopathy; clinically significant hemorrhagic symptoms within 1 month prior to the first dose (including but not limited to gastrointestinal bleeding, hemoptysis, epistaxis) History of myocarditis, cardiomyopathy, or malignant arrhythmia History of immunodeficiency; positive HIV antibody test; current long-term use of systemic corticosteroids or other immunosuppressants; active autoimmune disease requiring systemic treatment within the past two years. Known active tuberculosis (TB). Known active syphilis infection. Administration of a live or live-attenuated vaccine within 30 days prior to the first dose. History of mental illness, drug abuse, alcoholism, or substance abuse. Pregnant or lactating women.
引自 ClinicalTrials.gov, NCT07324473, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07324473,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。